Bausch + Lomb (BLCO) is drawing fresh attention after two linked catalysts. The company just launched its EyeGility Inserter in the U.S., and investors are watching closely ahead of this week's earnings report.

The market reaction around the EyeGility launch and upcoming earnings has come alongside a 90-day share price return of 8.28%, while the 1-year total shareholder return of 13.38% contrasts with a 3-year total shareholder return that declined 14.16%. This suggests that momentum has recently improved.

If you are looking beyond Bausch + Lomb and want to see what else is gaining attention in healthcare technology, now could be a good time to review 40 healthcare AI stocks.

After the recent share price climb and the EyeGility launch, the real test for Bausch + Lomb now is price. Does the current valuation still leave enough upside to justify the risks you would be taking from here?

Most Popular Narrative: 57.7% Undervalued

The most followed narrative on Bausch + Lomb values the stock at $39.23 a share, which sits well above the recent $16.61 close. That gap is driving a very different conversation to the one you see in the short term price moves.

For more than a week following the company’s Annual General Meeting (AGM), shareholders have been left without a single published result, filing, press release, or confirmation of what occurred inside the meeting. This absence of disclosure is not normal, is not industry standard, and is not aligned with the obligations of a publicly traded company.

The fair value in this narrative leans heavily on how fast earnings could recover from current losses and what sort of margins Bausch + Lomb might sustain once profitability is reached. It also incorporates specific assumptions about how revenue from Vision Care, Pharmaceuticals, and Surgical could compound together over time. Curious which of those levers does the most work in getting from $16.61 to $39.23? The details sit inside the narrative and may surprise you.

Result: Fair Value of $39.23 (UNDERVALUED)

However, this Bausch + Lomb story still carries real risks, including ongoing net losses of US$219 million, as well as the shareholder governance concerns highlighted in the AGM narrative.

Next Steps

Does this Bausch + Lomb story feel more optimistic or cautious to you right now? If you want to move quickly and ground your own view in the underlying data, start by reviewing the 3 key rewards

Looking for more investment ideas beyond Bausch + Lomb?

Once you have formed a view on Bausch + Lomb, consider broadening your watchlist so you are not relying on a single story.

• Spot potential value opportunities early by scanning 49 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet.
• Prioritise resilience by reviewing 83 resilient stocks with low risk scores that score well on balance sheet strength and lower overall risk profiles.
• Hunt for future leaders by checking the screener containing 20 high quality undiscovered gems that remain off most radars despite solid underlying numbers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.